Close Menu

BRCA Biomarkers

News and reporting on BRCA biomarkers.

The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib. 

Although Tesaro used Myriad's BRCA and HRD tests to stratify patients, in the NOVA trial all recurrent ovarian cancer patients benefitted from niraparib. 

According to Myriad, the NOVA study shows that myChoice HRD can double the number of ovarian cancer patients who will respond to niraparib compared to other tests.

Pages